Cytokine-modulating strategies and newer cytokine targets for arthritis therapy

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2015, Pages 887-906

  Venkatesha, Shivaprasad H ^a   Dudics, Steven ^a   Acharya, Bodhraj ^a   Moudgil, Kamal D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; Autoimmunity; Biologics; Cytokines; Gene therapy; Inflammation; Interleukins; Rheumatoid arthritis; SiRNA

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BRODALUMAB; CANAKINUMAB; CYTOKINE; ETANERCEPT; GEVOKIZUMAB; GOLIMUMAB; GUSELKUMAB; HEAT SHOCK PROTEIN 65; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 32; INTERLEUKIN 34; INTERLEUKIN 35; IXEKIZUMAB; LY 2189102; MAB 406; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SECUKINUMAB; SUPPRESSOR OF CYTOKINE SIGNALING; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA;

ARTHRITIS; AUTOIMMUNITY; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE THERAPY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; GENETICS; IMMUNOLOGY; METABOLISM;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CYTOKINES; GENETIC THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84920272734     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16010887     Document Type: Review

References (124)

1. Astry, B.; Harberts, E.; Moudgil, K.D. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J. Interferon Cytokine Res. 2011, 31, 927–940.
2. Clavel, G.; Thiolat, A.; Boissier, M.C. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Jt. Bone Spine2013, 80, 449–453.
3. Leng, R.X.; Pan, H.F.; Tao, J.H.; Ye, D.Q. IL-19, IL-20 and IL-24: Potential therapeutic targets for autoimmune diseases. Expert Opin. Ther. Targets2011, 15, 119–126.
4. Garlanda, C.; Dinarello, C.A.; Mantovani, A. The interleukin-1 family: Back to the future. Immunity2013, 39, 1003–1018.
5. Gaffen, S.L.; Jain, R.; Garg, A.V.; Cua, D.J. The IL-23–IL-17 immune axis: From mechanisms to therapeutic testing. Nat. Rev. Immunol. 2014, 14, 585–600.
6. Tang, C.; Chen, S.; Qian, H.; Huang, W. Interleukin-23: As a drug target for autoimmune inflammatory diseases. Immunology2012, 135, 112–124.
7. Bettelli, E.; Korn, T.; Kuchroo, V.K. Th17: The third member of the effector T cell trilogy. Curr. Opin. Immunol. 2007, 19, 652–657.
8. Rajaiah, R.; Puttabyatappa, M.; Polumuri, S.K.; Moudgil, K.D. Interleukin-27 and interferon-γ are involved in regulation of autoimmune arthritis. J. Biol. Chem. 2011, 286, 2817–2825.
9. Adamopoulos, I.E.; Pflanz, S. The emerging role of interleukin 27 in inflammatory arthritis and bone destruction. Cytokine Growth Factor Rev.2013, 24, 115–121.
10. Clark, I.A. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 2007, 18, 335–343.
11. Walsh, L.J.; Trinchieri, G.; Waldorf, H.A.; Whitaker, D.; Murphy, G.F. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc. Natl. Acad. Sci. USA1991, 88, 4220–4224.
12. Wajant, H.; Pfizenmaier, K.; Scheurich, P. Tumor necrosis factor signaling. Cell Death Differ. 2003, 10, 45–65.
13. Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell2001, 104, 487–501.
14. Chen, G.; Goeddel, D.V. TNF-R1 signaling: A beautiful pathway. Science2002, 296, 1634–1635.
15. Kant, S.; Swat, W.; Zhang, S.; Zhang, Z.-Y.; Neel, B.G.; Flavell, R.A.; Davis, R.J. TNF-stimulated MAP kinase activation mediated by a RHO family gtpase signaling pathway. Genes Dev. 2011, 25, 2069–2078.
16. Hot, A.; Miossec, P. Effects of interleukin (IL)-17a and IL-17F in human rheumatoid arthritis synoviocytes. Ann. Rheum. Dis. 2011, 70, 727–732.
17. Shabgah, A.G.; Fattahi, E.; Shahneh, F.Z. Interleukin-17 in human inflammatory diseases. Postep. Dermatol. Alergol. 2014, 31, 256–261.
18. Sarkar, S.; Justa, S.; Brucks, M.; Endres, J.; Fox, D.A.; Zhou, X.; Alnaimat, F.; Whitaker, B.; Wheeler, J.C.; Jones, B.H.; et al. Interleukin (IL)-17a, f and af in inflammation: A study in collagen-induced arthritis and rheumatoid arthritis. Clin. Exp. Immunol. 2014, 177, 652–661.
19. Mertens, M.; Singh, J.A. Anakinra for rheumatoid arthritis: A systematic review. J. Rheumatol. 2009, 36, 1118–1125.
20. Goh, A.X.; Bertin-Maghit, S.; Ping Yeo, S.; Ho, A.W.; Derks, H.; Mortellaro, A.; Wang, C.I. A novel human anti-interleukin-1beta neutralizing monoclonal antibody showing in vivo efficacy. MAbs2014, 6, 765–773.
21. Chakraborty, A.; Tannenbaum, S.; Rordorf, C.; Lowe, P.J.; Floch, D.; Gram, H.; Roy, S. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin. Pharmacokinet. 2012, 51, e1–e18.
22. Geiler, J.; McDermott, M.F. Gevokizumab, an anti-IL-1β MAB for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr. Opin. Mol. Ther. 2010, 12, 755–769.
23. Bihorel, S.; Fiedler-Kelly, J.; Ludwig, E.; Sloan-Lancaster, J.; Raddad, E. Population pharmacokinetic modeling of ly2189102 after multiple intravenous and subcutaneous administrations. AAPS J. 2014, 16, 1009–1017.
24. McDermott, M.F. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today2009, 45, 423–430.
25. Liang, B.; Gardner, D.B.; Griswold, D.E.; Bugelski, P.J.; Song, X.Y. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology2006, 119, 296–305.
26. LaSpina, M.; Tripathi, S.; Gatto, L.A.; Bruch, D.; Maier, K.G.; Kittur, D.S. An interleukin-6-neutralizing antibody prevents cyclosporine-induced nephrotoxicity in mice. J. Surg. Res. 2008, 148, 121–125.
27. Straub, R.H.; Harle, P.; Yamana, S.; Matsuda, T.; Takasugi, K.; Kishimoto, T.; Nishimoto, N. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2006, 54, 1778–1785.
28. Semerano, L.; Thiolat, A.; Minichiello, E.; Clavel, G.; Bessis, N.; Boissier, M.C. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase ii investigational drugs. Expert Opin. Investig. Drugs2014, 23, 979–999.
29. Nishimoto, N.; Kishimoto, T.; Yoshizaki, K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann. Rheum. Dis. 2000, 59(Suppl. S1), i21–i27.
30. Lou, H.; Zong, Y.; Ge, Y.R.; Cheng, J.W.; Wei, R.L. Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma. Curr. Med. Res. Opin. 2014, 30, 1367–1373.
31. St Clair, E.W.; van der Heijde, D.M.; Smolen, J.S.; Maini, R.N.; Bathon, J.M.; Emery, P.; Keystone, E.; Schiff, M.; Kalden, J.R.; Wang, B.; et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheumatol. 2004, 50, 3432–3443.
32. Wiens, A.; Correr, C.J.; Venson, R.; Otuki, M.F.; Pontarolo, R. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol. Int. 2010, 30, 1063–1070.
33. Moreland, L.W.; Baumgartner, S.W.; Schiff, M.H.; Tindall, E.A.; Fleischmann, R.M.; Weaver, A.L.; Ettlinger, R.E.; Cohen, S.; Koopman, W.J.; Mohler, K.; et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-fc fusion protein. N. Engl. J. Med. 1997, 337, 141–147.
34. Keystone, E.C.; Genovese, M.C.; Klareskog, L.; Hsia, E.C.; Hall, S.T.; Miranda, P.C.; Pazdur, J.; Bae, S.C.; Palmer, W.; Zrubek, J.; et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD study. Ann. Rheum. Dis. 2009, 68, 789–796.
35. Langley, R.G.; Elewski, B.E.; Lebwohl, M.; Reich, K.; Griffiths, C.E.; Papp, K.; Puig, L.; Nakagawa, H.; Spelman, L.; Sigurgeirsson, B.; et al. Secukinumab in plaque psoriasis—Results of two phase 3 trials. N. Engl. J. Med. 2014, 371, 326–338.
36. Patel, D.D.; Lee, D.M.; Kolbinger, F.; Antoni, C. Effect of IL-17a blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 2013, 72 (Suppl. S2), ii116–ii123.
37. Leonardi, C.; Matheson, R.; Zachariae, C.; Cameron, G.; Li, L.; Edson-Heredia, E.; Braun, D.; Banerjee, S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 2012, 366, 1190–1199.
38. Mease, P.J.; Genovese, M.C.; Greenwald, M.W.; Ritchlin, C.T.; Beaulieu, A.D.; Deodhar, A.; Newmark, R.; Feng, J.; Erondu, N.; Nirula, A. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 2014, 370, 2295–2306.
39. Sandborn, W.J.; Gasink, C.; Gao, L.L.; Blank, M.A.; Johanns, J.; Guzzo, C.; Sands, B.E.; Hanauer, S.B.; Targan, S.; Rutgeerts, P.; et al. Ustekinumab induction and maintenance therapy in refractory crohn’s disease. N. Engl. J. Med. 2012, 367, 1519–1528.
40. Sofen, H.; Smith, S.; Matheson, R.T.; Leonardi, C.L.; Calderon, C.; Brodmerkel, C.; Li, K.; Campbell, K.; Marciniak, S.J., Jr.; Wasfi, Y.; et al. Guselkumab (an IL-23-specific mab) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J. Allergy Clin. Immunol. 2014, 133, 1032–1040.
41. Yoshida, Y.; Tanaka, T. Interleukin 6 and rheumatoid arthritis. BioMed Res. Int. 2014, 2014, doi:10.1155/2014/698313.
42. Calabrese, L.H.; Rose-John, S. IL-6 biology: Implications for clinical targeting in rheumatic disease. Nat. Rev. 2014, 10, 720–727.
43. Pan, R.Y.; Chen, S.L.; Xiao, X.; Liu, D.W.; Peng, H.J.; Tsao, Y.P. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheumatol. 2000, 43, 289–297.
44. Evans, C.H.; Ghivizzani, S.C.; Herndon, J.H.; Wasko, M.C.; Reinecke, J.; Wehling, P.; Robbins, P.D. Clinical trials in the gene therapy of arthritis. Clin. Orthop. Relat. Res. 2000, 379, S300–S307.
45. Wehling, P.; Reinecke, J.; Baltzer, A.W.; Granrath, M.; Schulitz, K.P.; Schultz, C.; Krauspe, R.; Whiteside, T.W.; Elder, E.; Ghivizzani, S.C.; et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum. Gene Ther. 2009, 20, 97–101.
46. Bloquel, C.; Bessis, N.; Boissier, M.C.; Scherman, D.; Bigey, P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-α soluble receptor I variants. Hum. Gene Ther. 2004, 15, 189–201.
47. Kim, J.M.; Ho, S.H.; Hahn, W.; Jeong, J.G.; Park, E.J.; Lee, H.J.; Yu, S.S.; Lee, C.S.; Lee, Y.W.; Kim, S. Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Ther. 2003, 10, 1216–1224.
48. Mease, P.J.; Hobbs, K.; Chalmers, A.; El-Gabalawy, H.; Bookman, A.; Keystone, E.; Furst, D.E.; Anklesaria, P.; Heald, A.E. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: A phase 1 dose-escalation safety and tolerability study. Ann. Rheum. Dis. 2009, 68, 1247–1254.
49. Adriaansen, J.; Kuhlman, R.R.; van Holten, J.; Kaynor, C.; Vervoordeldonk, M.J.; Tak, P.P. Intraarticular interferon-beta gene therapy ameliorates adjuvant arthritis in rats. Hum. Gene Ther. 2006, 17, 985–996.
50. Woods, J.M.; Tokuhira, M.; Berry, J.C.; Katschke, K.J., Jr.; Kurata, H.; Damergis, J.A., Jr.; Arai, K.; Koch, A.E. Interleukin-4 adenoviral gene therapy reduces production of inflammatory cytokines and prostaglandin e2 by rheumatoid arthritis synovium ex vivo. J. Investig. Med. 1999, 47, 285–292.
51. Vermeij, E.A.; Broeren, M.G.; Bennink, M.B.; Arntz, O.J.; Gjertsson, I.; van Lent P, L.E.M.; van den Berg, W.B.; Koenders, M.I.; van de Loo, F.A. Disease-regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis. Ann. Rheum. Dis. 2014, doi:10.1136/annrheumdis-2014-205223.
52. Smeets, R.L.; van de Loo, F.A.; Arntz, O.J.; Bennink, M.B.; Joosten, L.A.; van den Berg, W.B. Adenoviral delivery of IL-18 binding protein c ameliorates collagen-induced arthritis in mice. Gene Ther.2003, 10, 1004–1011.
53. Brennan, F.M.; McInnes, I.B. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Investig. 2008, 118, 3537–3545.
54. Singh, R.P.; Hasan, S.; Sharma, S.; Nagra, S.; Yamaguchi, D.T.; Wong, D.; Bh, H.; Hossain, A. Th17 cells in inflammation and autoimmunity. Autoimmun. Rev. 2014, 13, 1174–1181.
55. Shetty, A.; Hanson, R.; Korsten, P.; Shawagfeh, M.; Arami, S.; Volkov, S.; Vila, O.; Swedler, W.; Shunaigat, A.N.; Smadi, S.; et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des. Dev. Ther.2014, 8, 349–364.
56. Alghasham, A.; Rasheed, Z. Therapeutic targets for rheumatoid arthritis: Progress and promises. Autoimmunity2014, 47, 77–94.
57. Bongartz, T.; Sutton, A.J.; Sweeting, M.J.; Buchan, I.; Matteson, E.L.; Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA2006, 295, 2275–2285.
58. Cantini, F.; Niccoli, L.; Goletti, D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: Data from clinical trials and national registries. J. Rheumatol. Suppl. 2014, 91, 56–64.
59. Choy, E.H.; Kavanaugh, A.F.; Jones, S.A. The problem of choice: Current biologic agents and future prospects in RA. Nat. Rev. Rheumatol. 2013, 9, 154–163.
60. Kim, E.Y.; Chi, H.H.; Rajaiah, R.; Moudgil, K.D. Exogenous tumour necrosis factor alpha induces suppression of autoimmune arthritis. Arthritis Res. Ther. 2008, 10, R38.
61. Williams, R.O. Paradoxical effects of tumour necrosis factor-α in adjuvant-induced arthritis. Arthritis Res. Ther. 2008, 10, 113.
62. Elicabe, R.J.; Cargnelutti, E.; Serer, M.I.; Stege, P.W.; Valdez, S.R.; Toscano, M.A.; Rabinovich, G.A.; Di Genaro, M.S. Lack of TNFR p55 results in heightened expression of IFN-γ and IL-17 during the development of reactive arthritis. J. Immunol.2010, 185, 4485–4495.
63. Masli, S.; Turpie, B. Anti-inflammatory effects of tumour necrosis factor (TNF)-α are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-β-treated antigen-presenting cells. Immunology2009, 127, 62–72.
64. Zakharova, M.; Ziegler, H.K. Paradoxical anti-inflammatory actions of TNF-α: Inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J. Immunol.2005, 175, 5024–5033.
65. Zagury, D.; Burny, A.; Gallo, R.C. Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines. Proc. Natl. Acad. Sci. USA2001, 98, 8024–8029.
66. Spohn, G.; Keller, I.; Beck, M.; Grest, P.; Jennings, G.T.; Bachmann, M.F. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 2008, 38, 877–887.
67. Bertin-Maghit, S.M.; Capini, C.J.; Bessis, N.; Chomilier, J.; Muller, S.; Abbas, A.; Autin, L.; Spadoni, J.L.; Rappaport, J.; Therwath, A.; et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1β peptides designed by molecular modelling. Vaccine2005, 23, 4228–4235.
68. Dalum, I.; Butler, D.M.; Jensen, M.R.; Hindersson, P.; Steinaa, L.; Waterston, A.M.; Grell, S.N.; Feldmann, M.; Elsner, H.I.; Mouritsen, S. Therapeutic antibodies elicited by immunization against TNF-α. Nat. Biotechnol. 1999, 17, 666–669.
69. Salomon, I.; Netzer, N.; Wildbaum, G.; Schif-Zuck, S.; Maor, G.; Karin, N. Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis. J. Immunol. 2002, 169, 2685–2693.
70. Ratsimandresy, R.A.; Duvallet, E.; Assier, E.; Semerano, L.; Delavallee, L.; Bessis, N.; Zagury, J.F.; Boissier, M.C. Active immunization against IL-23p19 improves experimental arthritis. Vaccine2011, 29, 9329–9336.
71. Hilton, S.W.D.J. Inhibitors of cytokine signal transduction. J. Biol. Chem. 2004, 279, 821–824.
72. Gaestel, M.; Mengel, A.; Bothe, U.; Asadullah, K. Protein kinases as small molecule inhibitor targets in inflammation. Curr. Med. Chem. 2007, 14, 2214–2234.
73. Milici, A.J.; Kudlacz, E.M.; Audoly, L.; Zwillich, S.; Changelian, P. Cartilage preservation by inhibition of janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther. 2008, 10, R14.
74. Lundquist, L.M.; Cole, S.W.; Sikes, M.L. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J. Orthop. 2014, 5, 504–511.
75. Maiga, M.; Lun, S.; Guo, H.; Winglee, K.; Ammerman, N.C.; Bishai, W.R. Risk of tuberculosis reactivation with tofacitinib (cp-690550). J. Infect. Dis. 2012, 205, 1705–1708.
76. Venkatesha, S.H.; Berman, B.M.; Moudgil, K.D. Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis. Bioorg. Med. Chem. 2011, 19, 21–29.
77. Nanjundaiah, S.M.; Venkatesha, S.H.; Yu, H.; Tong, L.; Stains, J.P.; Moudgil, K.D. Celastrus and its bioactive celastrol protect against bone damage in autoimmune arthritis by modulating osteoimmune cross-talk. J. Biol. Chem. 2012, 287, 22216–22226.
78. Venkatesha, S.H.; Astry, B.; Nanjundaiah, S.M.; Yu, H.; Moudgil, K.D. Suppression of autoimmune arthritis by celastrus-derived celastrol through modulation of pro-inflammatory chemokines. Bioorg. Med. Chem. 2012, 20, 5229–5234.
79. Matsunaga, N.; Tsuchimori, N.; Matsumoto, T.; Ii, M. Tak-242 (resatorvid), a small-molecule inhibitor of toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol. Pharmacol. 2010, 79, 34–41.
80. McCormack, W.J.; Parker, A.E.; O’Neill, L.A. Toll-like receptors and nod-like receptors in rheumatic diseases. Arthritis Res. Ther. 2009, 11, 243.
81. Evans, C.H.; Ghivizzani, S.C.; Robbins, P.D. Getting arthritis gene therapy into the clinic. Nat. Rev. 2011, 7, 244–249.
82. Jorgensen, C.; Apparailly, F. Prospects for gene therapy in inflammatory arthritis. Best Pract. Res. 2010, 24, 541–552.
83. Nakasato, M.; Nonomura, Y.; Miyasaka, N.; Kohsaka, H. The gene delivery system for rheumatoid synovium. Jpn. J. Clin. Immunol. 2008, 31, 17–22.
84. Traister, R.S.; Hirsch, R. Gene therapy for arthritis. Mod. Rheumatol. 2008, 18, 2–14.
85. Woods, A.M.; Thompson, S.J.; Wooley, P.H.; Panayi, G.; Klavinskis, L.S. Immune modulation of collagen-induced arthritis by intranasal cytokine gene delivery: A model for the therapy of rheumatoid arthritis. Arthritis Rheumatol. 2005, 52, 3761–3771.
86. Schmidt-Weber, C.B.; Pohlers, D.; Siegling, A.; Schadlich, H.; Buchner, E.; Volk, H.D.; Palombo-Kinne, E.; Emmrich, F.; Kinne, R.W. Cytokine gene activation in synovial membrane, regional lymph nodes, and spleen during the course of rat adjuvant arthritis. Cell Immunol. 1999, 195, 53–65.
87. Ji, J.D.; Lee, W.J. Interleukin-18 gene polymorphisms and rheumatoid arthritis: A meta-analysis. Gene2013, 523, 27–32.
88. Zhang, W.; Cong, XL.; Qin, Y.H.; He, Z.W.; He, D.Y.; Dai, S.M. IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis. Inflammation2013, 36, 103–109.
89. Tak, P.P. IFN-P in rheumatoid arthritis. Front. Biosci. 2004, 9, 3242–3247.
90. Lee, S.J.; Lee, A.; Hwang, S.R.; Park, J.S.; Jang, J.; Huh, M.S.; Jo, D.G.; Yoon, S.Y.; Byun, Y.; Kim, S.H.; et al. TNF-α gene silencing using polymerized sirna/thiolated glycol chitosan nanoparticles for rheumatoid arthritis. Mol. Ther. 2014, 22, 397–408.
91. Komano, Y.; Yagi, N.; Onoue, I.; Kaneko, K.; Miyasaka, N.; Nanki, T. Arthritic joint-targeting small interfering RNA-encapsulated liposome: Implication for treatment strategy for rheumatoid arthritis. J. Pharmacol. Exp. Ther. 2012, 340, 109–113.
92. Scheinman, R.I.; Trivedi, R.; Vermillion, S.; Kompella, U.B. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine2011, 6, 1669–1682.
93. Xue, Y.; Yang, Y.; Su, Z.; Barnie, P.A.; Zheng, D.; Zhang, Y.; Xu, Y.; Wang, S.; Xu, H. Local delivery of T-bet shRNA reduces inflammation in collagen II-induced arthritis via downregulation of IFN-γ and IL-17. Mol. Med. Rep. 2014, 9, 899–903.
94. Fedorov, Y.; Anderson, E.M.; Birmingham, A.; Reynolds, A.; Karpilow, J.; Robinson, K.; Leake, D.; Marshall, W.S.; Khvorova, A. Off-target effects by sirna can induce toxic phenotype. RNA2006, 12, 1188–1196.
95. Kleinman, M.E.; Yamada, K.; Takeda, A.; Chandrasekaran, V.; Nozaki, M.; Baffi, J.Z.; Albuquerque, R.J.; Yamasaki, S.; Itaya, M.; Pan, Y.; et al. Sequence- and target-independent angiogenesis suppression by sirna via TLR3. Nature2008, 452, 591–597.
96. Satpute, S.R.; Durai, M.; Moudgil, K.D. Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis. Semin. Arthritis Rheum. 2008, 38, 195–207.
97. Satpute, S.R.; Soukhareva, N.; Scott, D.W.; Moudgil, K.D. Mycobacterial Hsp65-IgG-expressing tolerogenic B cells confer protection against adjuvant-induced arthritis in Lewis rats. Arthritis Rheumatol. 2007, 56, 1490–1496.
98. Thomas, C.E.; Ehrhardt, A.; Kay, M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4, 346–358.
99. Williams, D.A.; Thrasher, A.J. Concise review: Lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases. Stem Cells Transl. Med. 2014, 3, 636–642.
100. Sade, R.M.; Khushf, G. Gene therapy: Ethical and social issues. J. South Carol. Med. Assoc. 1998,94,406-410
101. Wivel, N.A.; Walters, L. Germ-line gene modification and disease prevention: Some medical and ethical perspectives. Science1993, 262, 533–538.
102. Kim, S. Interleukin-32 in inflammatory autoimmune diseases. Immune Netw. 2014, 14, 123–127.
103. Joosten, L.A.; Netea, M.G.; Kim, S.H.; Yoon, D.Y.; Oppers-Walgreen, B.; Radstake, T.R.; Barrera, P.; van de Loo, F.A.; Dinarello, C.A.; van den Berg, W.B. II-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA2006, 103, 3298–3303.
104. Shoda, H.; Fujio, K.; Yamaguchi, Y.; Okamoto, A.; Sawada, T.; Kochi, Y.; Yamamoto, K. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res. Ther. 2006, 8, R166.
105. Alsaleh, G.; Sparsa, L.; Chatelus, E.; Ehlinger, M.; Gottenberg, J.E.; Wachsmann, D.; Sibilia, J. Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res. Ther. 2010, 12, R135.
106. Jeong, H.J.; Nam, S.Y.; Oh, H.A.; Han, N.R.; Kim, Y.S.; Moon, P.D.; Shin, S.Y.; Kim, M.H.; Kim, H.M. Interleukin-32-induced thymic stromal lymphopoietin plays a critical role in macrophage differentiation through the activation of caspase-1 in vitro. Arthritis Res. Ther. 2012, 14, R259.
107. Son, M.H.; Jung, M.Y.; Choi, S.; Cho, D.; Kim, T.S. IL-32γ induces chemotaxis of activated t cells via dendritic cell-derived ccl5. Biochem. Biophys. Res. Commun. 2014, 450, 30–35.
108. Moon, Y.M.; Yoon, B.Y.; Her, Y.M.; Oh, H.J.; Lee, J.S.; Kim, K.W.; Lee, S.Y.; Woo, Y.J.; Park, K.S.; Park, S.H.; et al. IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res. Ther. 2012, 14, R246.
109. Dinarello, C.A.; Kim, S.H. IL-32, a novel cytokine with a possible role in disease. Ann. Rheum. Dis. 2006, 65 (Suppl. S3), iii61–iii64.
110. Bostrom, E.A.; Lundberg, P. The newly discovered cytokine IL-34 is expressed in gingival fibroblasts, shows enhanced expression by pro-inflammatory cytokines, and stimulates osteoclast differentiation. PLoS One2013, 8, e81665.
111. Hwang, S.J.; Choi, B.; Kang, S.S.; Chang, J.H.; Kim, Y.G.; Chung, Y.H.; Sohn, D.H.; So, M.W.; Lee, C.K.; Robinson, W.H.; et al. Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res. Ther. 2012, 14, R14.
112. Chen, Z.; Buki, K.; Vaaraniemi, J.; Gu, G.; Vaananen, H.K. The critical role of IL-34 in osteoclastogenesis. PLoS One2011, 6, e18689.
113. Baud'huin, M.; Renault, R.; Charrier, C.; Riet, A.; Moreau, A.; Brion, R.; Gouin, F.; Duplomb, L.; Heymann, D. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in rankl-induced osteoclastogenesis. J. Pathol. 2010, 221, 77–86.
114. Chang, S.H.; Choi, B.Y.; Choi, J.; Yoo, J.J.; Ha, Y.J.; Cho, H.J.; Kang, E.H.; Song, Y.W.; Lee, Y.J. Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis. Rheumatol. Int. 2014, doi:10.1007/s00296-014-3056-5.
115. Chemel, M.; Le Goff, B.; Brion, R.; Cozic, C.; Berreur, M.; Amiaud, J.; Bougras, G.; Touchais, S.; Blanchard, F.; Heymann, M.F.; et al. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann. Rheum. Dis. 2012, 71, 150–154.
116. Tian, Y.; Shen, H.; Xia, L.; Lu, J. Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: Possible association with disease progression via interleukin-17 production. J. Interferon Cytokine Res. 2013, 33, 398–401.
117. Moon, S.J.; Hong, Y.S.; Ju, J.H.; Kwok, S.K.; Park, S.H.; Min, J.K. Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis. J. Rheumatol. 2013, 40, 1842–1849.
118. Collison, L.W.; Chaturvedi, V.; Henderson, A.L.; Giacomin, P.R.; Guy, C.; Bankoti, J.; Finkelstein, D.; Forbes, K.; Workman, C.J.; Brown, S.A.; et al. IL-35-mediated induction of a potent regulatory t cell population. Nat. Immunol. 2010, 11, 1093–1101.
119. Collison, L.W.; Delgoffe, G.M.; Guy, C.S.; Vignali, K.M.; Chaturvedi, V.; Fairweather, D.; Satoskar, A.R.; Garcia, K.C.; Hunter, C.A.; Drake, C.G.; et al. The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 2012, 13, 290–299.
120. Niedbala, W.; Wei, X.Q.; Cai, B.; Hueber, A.J.; Leung, B.P.; McInnes, I.B.; Liew, F.Y. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of th17 cells. Eur. J. Immunol. 2007, 37, 3021–3029.
121. Kochetkova, I.; Golden, S.; Holderness, K.; Callis, G.; Pascual, D.W. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J. Immunol.2010, 184, 7144–7153.
122. Bettini, M.; Castellaw, A.H.; Lennon, G.P.; Burton, A.R.; Vignali, D.A. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes2012, 61, 1519–1526.
123. Wirtz, S.; Billmeier, U.; McHedlidze, T.; Blumberg, R.S.; Neurath, M.F. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology2011, 141, 1875–1886.
124. Thiolat, A.; Denys, A.; Petit, M.; Biton, J.; Lemeiter, D.; Herve, R.; Lutomski, D.; Boissier, M.C.; Bessis, N. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine2014, 69, 87–93.